Senescence in pancreatic carcinogenesis: From signalling to chromatin remodelling and epigenetics

Gut

Volumn 62, Issue 9, 2013, Pages 1364-1372

  Singh, Shiv K ^a   Ellenrieder, Volker ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; CELL CYCLE PROTEIN 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA METHYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; HISTONE METHYLTRANSFERASE; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR NFAT; UNINDEXED DRUG;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CDKN2A GENE; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; DRUG EFFECT; EPIGENETICS; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENE SILENCING; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; SENESCENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOGENESIS; CELL AGING; CHROMATIN ASSEMBLY AND DISASSEMBLY; EPIGENESIS, GENETIC; GENE SILENCING; GENES, P16; GENES, RAS; HUMANS; MICE; MODELS, ANIMAL; MUTATION; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84881549844     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302793     Document Type: Article

References (95)

1. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961;25:585-621.
2. Larsson LG. Cellular senescence - a barrier against tumor development? Semin Cancer Biol 2011;6:347-8.
3. Blackburn EH. Telomeres: no end in sight. Cell 1994;5:621-3. (Pubitemid 24175598)
4. Chen QM, Prowse KR, Tu VC, et al. Uncoupling the senescent phenotype from telomere shortening in hydrogen peroxide-treated fibroblasts. Exp Cell Res 2001;2:294-303. (Pubitemid 32980218)
5. Flores I, Cayuela ML, Blasco MA. Effects of telomerase and telomere length on epidermal stem cell behavior. Science 2005;5738:1253-6. (Pubitemid 41170921)
6. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007;2:223-33. (Pubitemid 47081143)
7. Harley CB, Vaziri H, Counter CM, et al. The telomere hypothesis of cellular aging. Exp Gerontol 1992;4:375-82.
8. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007;9:729-40. (Pubitemid 47312822)
9. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010;10:51-7.
10. Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;5:593-602. (Pubitemid 27152402)
11. DeNicola GM, Tuveson DA. RAS in cellular transformation and senescence. Eur J Cancer 2009;1:211-16.
12. Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005;7051:660-5. (Pubitemid 41117262)
13. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005;7051:725-30. (Pubitemid 41117277)
14. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature 2005;7051:642. (Pubitemid 41117258)
15. Pérez-Mancera PA, Guerra C, Barbacid M, et al. What we have learned about pancreatic cancer from mouse models. Gastroenterology 2012;5:1079-92.
16. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;6:437-50. (Pubitemid 38050041)
17. Morton JP, Timpson P, Karim SA, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 2010;1:246-51.
18. Kennedy AL, Morton JP, Manoharan I, et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 2011;1:36-49.
19. Itahana K, Campisi J, Dimri GP. Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. Methods Mol Biol 2007;371:21-31. (Pubitemid 350183415)
20. Narita M, Nünez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003;6:703-16. (Pubitemid 36724935)
21. Funayama R, Ishikawa F. Cellular senescence and chromatin structure. Chromosoma 2007;5:431-40. (Pubitemid 47456911)
22. Hoenicke L, Zender L. Immune surveillance of senescent cells - biological significance in cancer- and non-cancer pathologies. Carcinogenesis 2012;6:1123-6.
23. Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010;4:679-86.
24. Lin AW, Barradas M, Stone JC, et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998;12:3008-19. (Pubitemid 28469303)
25. Caldwell ME, DeNicola GM, Martins CP, et al. Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene 2012;12:1599-608.
26. Castellano E, Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2011;3:261-74.
27. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;17:4682-9. (Pubitemid 19213607)
28. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;4:549-54.
29. Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer. Oncogene 2007;22:3279-90. (Pubitemid 46763021)
30. Bianchi-Smiraglia A, Nikiforov MA. Controversial aspects of oncogene-induced senescence. Cell Cycle 2012;22:4147-51.
31. Dimauro T, David G. Ras-induced senescence and its physiological relevance in cancer. Curr Cancer Drug Targets 2010;8:869-76.
32. Nardella C, Clohessy JG, Alimonti A, et al. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011;7:503-11.
33. Sarkisian CJ, Keister BA, Stairs DB, et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007;5:493-505. (Pubitemid 46696530)
34. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;5:469-83. (Pubitemid 40719130)
35. Guerra C, Collado M, Navas C, et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011;6:728-39.
36. Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19(Arf) -p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006;15:5947-52.
37. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;7051:720-4. (Pubitemid 41117276)
38. Vredeveld LC, Possik PA, Smit MA, et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 2012;10:1055-69.
39. Kang TW, Yevsa T, Woller N, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011;7374:547-51.
40. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;6810:307-10.
41. Sperka T, Wang J, Rudolph KL. DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol 2012;9:579-90.
42. Reinhardt HC, Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet 2012;3:128-36.
43. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;10:731-7. (Pubitemid 33679835)
44. Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;5383:1674-7.
45. Ginsberg D, Mechta F, Yaniv M, et al. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 1991;22:9979-83. (Pubitemid 21915758)
46. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 2007;3:165-8.
47. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003;2:65-70. (Pubitemid 36135887)
48. Vernier M, Bourdeau V, Gaumont-Leclerc MF, et al. Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev 2011;1:41-50.
49. Jafarnejad SM, Li G. Regulation of p53 by ING family members in suppression of tumor initiation and progression. Cancer Metastasis Rev 2012;1-2:55-73.
50. Pearson M, Carbone R, Sebastiani C, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000; 6792:207-10. (Pubitemid 30469006)
51. Scarpa A, Capelli P, Mukai K, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993;5:1534-43. (Pubitemid 24058140)
52. Romagosa C, Simonetti S, López-Vicente L, et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 2011;18:2087-97.
53. Kocylowski MK, Halazonetis TD. SAHF, to senesce or not to senesce? Cell Cycle 2011;5:738-9.
54. Rea S, Eisenhaber F, O'Carroll D, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000;6796:593-9. (Pubitemid 30641039)
55. Changolkar LN, Costanzi C, Leu NA, et al. Developmental changes in histone macroH2A1-mediated gene regulation. Mol Cell Biol 2007;7:2758-64. (Pubitemid 46581363)
56. Funayama R, Saito M, Tanobe H, et al. Loss of linker histone H1 in cellular senescence. J Cell Biol 2006;6:869-80. (Pubitemid 44969193)
57. Fukushima N, Sato N, Ueki T, et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 2002;5:1573-81. (Pubitemid 34525637)
58. Moore PS, Orlandini S, Zamboni G, et al. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 2001;2:253-62. (Pubitemid 32113454)
59. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;2:211-26.
60. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;9:1731-4. (Pubitemid 27199667)
61. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;1:27-32. (Pubitemid 24274057)
62. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003;24:3112-26. (Pubitemid 38040774)
63. Berger SL, Kouzarides T, Shiekhattar R, et al. An operational definition of epigenetics. Genes Dev 2009;23:781-3.
64. Luger K, Richmond TJ. The histone tails of the nucleosome. Curr Opin Genet Dev 1998;2:140-6. (Pubitemid 28206276)
65. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;1:12-27.
66. Shain AH, Giacomini CP, Matsukuma K, et al. Convergent structural alterations define SWItch/Sucrose Non Fermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci USA 2012;9:253-9.
67. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012;491:399-405.
68. Schotta G, Ebert A, Reuter G. SU(VAR)3-9 is a conserved key function in heterochromatic gene silencing. Genetica 2003;2-3:149-58. (Pubitemid 36678725)
69. Lopez-Serra L, Esteller M. Proteins that bind methylated DNA and human cancer: reading the wrong words. Br J Cancer 2008;12:1881-5. (Pubitemid 351821557)
70. Zagni C, Chiacchio U, Rescifina A. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment. Curr Med Chem 2013; 20:167-85.
71. Luo J, Yu Y, Chang S, et al. DNA methylation fluctuation induced by virus infection differs between MD-resistant and -susceptible chickens. Front Genet Published Online First: 17 February 2012. doi: 10.3389/fgene.2012.00020
72. Fahrner JA, Eguchi S, Herman JG, et al. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002;24:7213-18. (Pubitemid 36025241)
73. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;2:141-9.
74. Ueki T, Walter KM, Skinner H, et al. Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived. Oncogene 2002;21:2114-17. (Pubitemid 34270901)
75. Sato N, Fukushima N, Matsubayashi H, et al. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 2003;23:1531-8.
76. Ueki T, Toyota M, Skinner H, et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res 2001;61:8540-6. (Pubitemid 33131137)
77. Costello JF, Plass C. Methylation matters. J Med Genet 2001;5:285-303. (Pubitemid 32433981)
78. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005;8:597-610. (Pubitemid 41044297)
79. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997;15:3126-30. (Pubitemid 27351723)
80. Grzenda A, Ordog T, Urrutia R. Polycomb and the emerging epigenetics of pancreatic cancer. J Gastrointest Can 2011;2:100-11.
81. McCleary-Wheeler AL, Lomberk GA, Weiss FU, et al. Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett 2013;2:212-21.
82. Schuettengruber B, Martinez AM, Iovino N, et al. Trithorax group proteins: switching genes on and keeping them active. Nat Rev Mol Cell Biol 2011;12:799-814.
83. Popov N, Gil J. Epigenetic regulation of the INK4b-ARF-INK4a locus: in sickness and in health. Epigenetics 2010;8:685-90.
84. Kia SK, Gorski MM, Giannakopoulos S, et al. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol Cell Biol 2008;10:3457-64. (Pubitemid 351657107)
85. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;5595:1039-43. (Pubitemid 35247314)
86. Mallen-St Clair J, Soydaner-Azeloglu R, Lee KE, et al. EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev 2012;5:439-44.
87. van Lohuizen M, Frasch M, Wientjens E, et al. Sequence similarity between the mammalian bmi-1 proto-oncogene and the Drosophila regulatory genes Psc and Su(z)2. Nature 1991;6342:353-5. (Pubitemid 21912509)
88. Martínez-Romero C, Rooman I, Skoudy A, et al. The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol 2009;2:205-13.
89. Fukuda A, Morris JP, Hebrok M. Bmi1 is required for regeneration of the exocrine pancreas in mice. Gastroenterology. 2012;143:821-31. e1-2.
90. Bruggeman SW, Valk-Lingbeek ME, van der Stoop PP, et al. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 2005;12:1438-43. (Pubitemid 41003010)
91. Gonzalez S, Klatt P, Delgado S, et al. Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 2006;40:702-6.
92. Prensner JR, Iyer MK, Balbin OA, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011;8:742-9.
93. Aguilo F, Zhou MM, Walsh MJ. Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer Res 2011;16:5365-9.
94. Kap KL, Li S, Muñoz-Cabello AM, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010;5:662-74.
95. Baumgart S, Glesel E, Singh G, et al. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology 2012;2:388-98.